Merz North America Congratulates Glenn Block on His Induction into the Canadian Healthcare Marketing Hall of Fame

  Merz North America Congratulates Glenn Block on His Induction into the
  Canadian Healthcare Marketing Hall of Fame

 Glenn Block, President & General Manager of Merz Pharma Canada, Ltd., to be
    recognized for his contributions to the Canadian healthcare community

Business Wire

GREENSBORO, N.C. -- April 10, 2013

Merz North America (affiliate of Merz Pharma Group) congratulates Glenn Block,
President and General Manager of Merz Pharma Canada, Ltd., who has been
selected for induction into the Canadian Healthcare Marketing Hall of Fame.
Block joined Merz in August 2007 and is responsible for all aspects of the
company’s strategy and operations in Canada. He also holds the distinction of
having built the Canadian organization from the ground up.

"Glenn has a proven track record in the development and commercialization of
pharmaceutical and OTC/OTX products in Canada, and he has made immense
contributions to the growth of our business in North America. His induction
into the Canadian Healthcare Marketing Hall of Fame is truly an appropriate
recognition of the impact he continues to have, not only on our business, but
within the Canadian healthcare community as a whole,” said Bill Humphries,
president & CEO of Merz North America.

The Canadian Healthcare Marketing Hall of Fame was established in 2006 in
conjunction with the National Pharmaceutical Congress, and the induction
ceremony will take place today, April 10, 2013 at the close of the 7th
National Pharmaceutical Congress in Toronto, Ontario. According to the
Chronicle Group of Companies, which organizes the event, inductees are chosen
based on distinctive contributions to the Canadian healthcare industry: “The
awards were established to honor healthcare marketers who have contributed to
our avocation and are an inspiration to others. These honorees were chosen
from this field of deserving candidates, but stand for, in the view of the
selection committee, a representative cross-section of the qualities that make
our business unique and fulfilling.^1”

“I am honored to be joining this cohort of innovative and inspiring healthcare
marketing professionals. Any success I have achieved in this industry is due
to a few individuals who have taken a chance on me during my career, as well
as to the great teams I have had the fortune to work with. I see this award as
representative of the status that Merz has achieved in the Canadian healthcare
community in a very short time, and I look forward to the continued growth and
success of our business here and across North America,” said Glenn Block,
President and General Manager, Merz Pharma Canada, Ltd.

Block has over 20 years of experience in the pharmaceutical industry, with
most of those years focused on the development and marketing of neurotoxins in
North America. Prior to joining Merz, he held senior-level marketing positions
with Biogen Idec Canada and Allergan, Inc. Block holds an Honors Bachelor of
Commerce degree from Queen’s University in Kingston, Ontario. He is based at
Merz offices in Toronto, Ontario.

About Merz North America

Merz North America is a specialty healthcare company that develops and
commercializes innovative treatment solutions in medical and aesthetic
dermatology, and neurology in the U.S. and Canada. Our ambition is to become a
recognized leader in the treatment of movement disorders, and in aesthetics
and dermatology. Our future is promising, and we are committed to advancing
new therapeutic options and improving patients’ lives. For more than 100
years, the development of our products has been based on Merz‘s commitment to
providing innovative medical approaches that earn trust of patients,
physicians and partners worldwide. Globally, the companies of Merz Pharma
Group are focused on medications for treating neurological and psychiatric
illnesses, and they have assumed a leading role in the field of Alzheimer’s
disease research. Founded in 1908, Merz Pharma Group is a privately owned
company headquartered in Frankfurt, Germany.

Strategic Canadian brands include Radiesse^® Volumizing Filler, Xeomin^®, and
Mederma^®. For more information about Merz Pharma Canada, Ltd. or their
products, please visit www.merzcanada.com. For information regarding Merz
products and operations in the United States, please visit www.merzusa.com or
www.merzaesthetics.com/en-US/.

IMPORTANT SAFETY INFORMATION for XEOMIN^®, INCLUDING BOXED WARNING


WARNING: DISTANT SPREAD OF TOXIN EFFECT
                                                                             
Postmarketing reports indicate that the effects of XEOMIN^®
(incobotulinumtoxinA) for injection, for intramuscular use, and all
botulinum toxin products may spread from the area of injection to produce
symptoms consistent with botulinum toxin effects. These may include
asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis,
dysphagia, dysphonia, dysarthria, urinary incontinence and breathing
difficulties. These symptoms have been reported hours to weeks after
injection. Swallowing and breathing difficulties can be life threatening and
there have been reports of death. The risk of symptoms is probably greatest  
in children treated for spasticity but symptoms can also occur in adults
treated for spasticity and other conditions, particularly in those patients
who have underlying conditions that would predispose them to these symptoms.
In unapproved uses, including spasticity in children and adults, and in
approved indications, cases of spread of effect have been reported at doses
comparable to those used to treat cervical dystonia and at lower doses.



Please see Full Prescribing Information, including Medication Guide for more
information.

CONTRAINDICATIONS

XEOMIN^® is contraindicated in patients with a known hypersensitivity to the
active substance botulinum toxin type A or to any of the components in the
formulation and in the presence of infection at the proposed injection
site(s), as injection could lead to severe local or disseminated infection.

WARNINGS AND PRECAUTIONS

  *The potency units of XEOMIN^® are not interchangeable with other
    preparations of botulinum toxin products. Therefore, units of biological
    activity of XEOMIN^® cannot be compared to or converted into units of any
    other botulinum toxin products.
  *Hypersensitivity reactions have been reported with botulinum toxin
    products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and
    dyspnea). If serious and/or immediate hypersensitivity reactions occur
    further injection of XEOMIN^® should be discontinued and appropriate
    medical therapy immediately instituted. Patients treated with botulinum
    toxin may require immediate medical attention should they develop problems
    with swallowing, speech, or respiratory disorders.
  *Treatment with XEOMIN^® and other botulinum toxin products can result in
    swallowing or breathing difficulties. Patients with pre-existing
    swallowing or breathing difficulties may be more susceptible to these
    complications. When distant effects occur, additional respiratory muscles
    may be involved Deaths as a complication of severe dysphagia have been
    reported after treatment with botulinum toxin. Dysphagia may persist for
    several months, which may require use of a feeding tube. Aspiration may
    result from severe dysphagiaThese reactions can occur within hours to
    weeks after injection with botulinum toxin. [See Boxed Warning].
  *Cervical Dystonia: Patients with smaller neck muscle mass and patients who
    require bilateral injections into the sternocleidomastoid muscles are at
    greater risk of dysphagia. Limiting the dose injected into the
    sternocleidomastoid muscle may decrease the occurrence of dysphagia.
  *Blepharospasm: Injection of XEOMIN^® into the orbicularis oculi muscle may
    lead to reduced blinking and corneal exposure with possible ulceration or
    perforation. Lower lid injections should not be repeated if diplopia
    occurred with previous botulinum toxin injections.
  *Glabellar Lines: Do not exceed the recommended dosage and frequency of
    administration of XEOMIN^®. In order to reduce the complication of ptosis
    the following steps should be taken:

       *Avoid injection near the levator palpebrae superioris, particularly
         in patients with larger brow depressor complexes.
       *Corrugator injections should be placed at least 1 cm above the bony
         supraorbital ridge.

  *Individuals with peripheral motor neuropathic diseases, amyotrophic
    lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia
    gravis or Lambert-Eaton syndrome) should be monitored particularly closely
    when given botulinum toxin. Patients with neuromuscular disorders may be
    at increased risk of clinically significant effects including severe
    dysphagia and respiratory compromise from typical doses of XEOMIN^®.
  *XEOMIN^® contains albumin. Based on effective donor screening and product
    manufacturing processes, it carries an extremely remote risk for
    transmission of viral diseases and Creutzfeldt-Jakob disease (CJD). No
    cases of transmission of viral diseases or CJD have ever been reported for
    albumin.

ADVERSE REACTIONS

Cervical Dystonia: The most commonly observed adverse reactions (incidence
≥10% of patients and twice the rate of placebo) for XEOMIN^® 120 Units and
XEOMIN^® 240 Units, respectively, were: dysphagia (13%, 18%), neck pain (7%,
15%), muscle weakness (7%, 11%), and musculoskeletal pain (7%, 4%).

Blepharospasm: The most common adverse reactions (incidence ≥10% of patients
and twice the rate of placebo) for XEOMIN^® were eyelid ptosis (19%), dry
mouth (16%), visual impairment (12%), diarrhea (8%), and headache (7%).

Glabellar Lines: The most common adverse reaction (incidence ≥ 2% of patients
and greater than placebo) for XEOMIN^® was Headache (5.4%).

DRUG INTERACTIONS

Concomitant treatment of XEOMIN^® and aminoglycoside antibiotics,
spectinomycin, or other agents that interfere with neuromuscular transmission
(e.g., tubocurarine-like agents), or muscle relaxants, should be observed
closely because the effect of XEOMIN may be potentiated.

The effect of administering different botulinum toxin products at the same
time or within several months of each other is unknown. Excessive
neuromuscular weakness may be exacerbated by administration of another
botulinum toxin prior to the resolution of the effects of a previously
administered botulinum toxin.

USE IN PREGNANCY

Pregnancy Category C: There are no adequate and well-controlled studies in
pregnant women. XEOMIN^® should be used during pregnancy only if the potential
benefit justifies the potential risk to the fetus.

PEDIATRIC USE

The safety and effectiveness of XEOMIN^® in patients less than 18 years of age
have not been established.

Please see Full Prescribing Information for more information on XEOMIN^®
(incobotulinumtoxinA) for injection, for intramuscular use, including complete
Boxed WARNING, available at www.Xeomin.com and at www.XeominAesthetic.com.

Botox^® is a registered trademark of Allergan.

^1 Source: National Pharmaceutical Congress

Contact:

Merz North America
Mariana Smith, 336-217-2636
Corporate Communications
msmith@merzusa.com